哪种组合最佳?血清生物标志物组合诊断假体周围关节感染的预测潜力比较
该研究基于单机构纵向数据库分析2017至2020年1363例翻修全关节置换患者(含273例假体周围关节感染,占20%),评估ESR、CRP、D-二聚体和IL-6单独及组合诊断PJI的效能。结果显示两标志物组合特异性高于CRP单独,三标志物组合敏感性高于CRP单独,但CRP总体诊断效能优于所有组合。作者认为常规组合检测可能过度且浪费资源。
要点
- 在翻修全膝关节置换中,CRP+ESR、CRP+D-二聚体、CRP+IL-6组合特异性均高于CRP单独(75.0%),但敏感性更低。
- 在翻修全髋关节置换中,上述两标志物组合特异性同样高于CRP单独(77.5%),敏感性亦更低。
- 总体比较,CRP单独诊断效能优于所有两标志物和三标志物组合。
核心结论
- 在翻修全膝关节置换和翻修全髋关节置换中诊断假体周围关节感染时,两标志物组合较CRP单独特异性更高,三标志物组合较CRP单独敏感性更高。
- 但与所有两标志物和三标志物组合相比,CRP单独显示出更优的总体诊断效能。
- 这些发现提示,常规组合检测标志物诊断假体周围关节感染可能过度且不必要地消耗资源,尤其在资源有限情况下。
研究设计与样本
- 单机构纵向数据库评估2017年至2020年所有接受翻修全关节置换的患者。
- 共分析1363例翻修全关节置换患者,包括715例翻修全膝关节置换和648例翻修全髋关节置换,其中假体周围关节感染273例(20%)。
- 假体周围关节感染在翻修全关节置换后依据2011年肌肉骨骼感染学会(MSIS)标准诊断。
- 系统收集所有患者的红细胞沉降率(ESR)、C反应蛋白(CRP)、D-二聚体和白细胞介素6(IL-6)。
主要发现
- 翻修全膝关节置换中,CRP+ESR组合敏感性78.3%、特异性88.8%、阳性预测值70.0%、阴性预测值92.5%;CRP+D-二聚体组合敏感性60.5%、特异性92.6%、阳性预测值63.4%、阴性预测值91.7%;CRP+IL-6组合敏感性38.5%、特异性100.0%、阳性预测值100.0%、阴性预测值92.9%。
- 翻修全膝关节置换中,CRP单独敏感性94.4%、特异性75.0%、阳性预测值55.5%、阴性预测值97.6%;上述两标志物组合特异性均高于CRP单独。
- 翻修全髋关节置换中,CRP+ESR组合敏感性70.1%、特异性88.8%、阳性预测值58.1%、阴性预测值93.1%;CRP+D-二聚体组合敏感性57.1%、特异性90.1%、阳性预测值43.2%、阴性预测值94.1%;CRP+IL-6组合敏感性21.4%、特异性98.4%、阳性预测值60.0%、阴性预测值91.7%。
- 翻修全髋关节置换中,CRP单独敏感性84.7%、特异性77.5%、阳性预测值45.4%、阴性预测值95.8%;上述两标志物组合特异性均高于CRP单独。
关键数值与推荐
- 翻修全膝关节置换中,CRP+ESR、CRP+D-二聚体、CRP+IL-6组合特异性分别为88.8%、92.6%、100.0%,均高于CRP单独的75.0%。
- 翻修全髋关节置换中,CRP+ESR、CRP+D-二聚体、CRP+IL-6组合特异性分别为88.8%、90.1%、98.4%,均高于CRP单独的77.5%。
- 翻修全膝关节置换中,CRP单独敏感性94.4%,高于CRP+ESR的78.3%、CRP+D-二聚体的60.5%、CRP+IL-6的38.5%。
- 翻修全髋关节置换中,CRP单独敏感性84.7%,高于CRP+ESR的70.1%、CRP+D-二聚体的57.1%、CRP+IL-6的21.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Without a gold-standard test, recent periprosthetic joint infections (PJI) literature has explored the utility of combining serological results, with promising findings. However, previous studies evaluated fewer than 200 patients and often studied only 1 to 2 test combinations. The purpose of this study was to accumulate a large single-institution cohort of revision total joint arthroplasty (rTJA) patients to determine the diagnostic utility of combination serum biomarkers to identify PJI. METHODS: A single institution longitudinal database was assessed to identify all patients who underwent rTJA from 2017 to 2020. There were 1,363 rTJA patients (715 rTKA patients and 648 rTHA patients) including 273 PJI cases (20%) analyzed. The PJI was diagnosed post-rTJA utilizing 2011 Musculoskeletal Infection Society (MSIS) criteria. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D-dimer, and interleukin 6 (IL-6) were systematically collected for all patients. RESULTS: The rTKA combination markers of CRP + ESR (sensitivity: 78.3%, specificity: 88.8%, positive predictive value (PPV): 70.0%, negative predictive value (NPV): 92.5%), CRP + D-dimer (sensitivity: 60.5%, specificity: 92.6%, PPV: 63.4%, NPV: 91.7%), and CRP + IL-6 (sensitivity: 38.5%, specificity: 100.0%, PPV: 100.0%, NPV: 92.9%) all yielded higher specificity than CRP alone (sensitivity: 94.4%, specificity: 75.0%, PPV: 55.5%, NPV: 97.6%). Similarly, the rTHA combination markers of CRP + ESR (sensitivity: 70.1%, specificity: 88.8%, PPV: 58.1%, NPV: 93.1%), CRP + D-dimer (sensitivity: 57.1%, specificity: 90.1%, PPV: 43.2%, NPV: 94.1%), and CRP + IL-6 (sensitivity: 21.4%, specificity: 98.4%, PPV: 60.0%, NPV: 91.7%) all yielded higher specificity than CRP alone (sensitivity: 84.7%, specificity: 77.5%, PPV: 45.4%, NPV: 95.8%). CONCLUSION: Overall, in diagnosing PJI for both rTKA and rTHA, 2-marker combinations yielded higher specificity, while 3-marker combinations yielded higher sensitivity compared to CRP alone. However, compared to all 2-marker and 3-marker combinations, CRP demonstrated superior overall diagnostic utility. These findings suggest that routine combination testing of markers for PJI diagnosis may be excessive and an unnecessary use of resources, especially in resource-limited situations.
引用
- Yu JS, Bornes TD, Youssef MP, et al. Which Combination is the Best? A Comparison of the Predictive Potential of Serum Biomarker Combinations to Diagnose Periprosthetic Joint Infection. J Arthroplasty. 2023. PMID: 37230226. doi:10.1016/j.arth.2023.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。